100%

Scanned image of the page. Keyboard directions: use + to zoom in, - to zoom out, arrow keys to pan inside the viewer.

Page Options

Share

Something wrong?

Something wrong with this page? Report problem.

Rights / Permissions

The University of Michigan Library provides access to these materials for educational and research purposes. These materials may be under copyright. If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission. If you have questions about the collection, please contact the Bentley Historical Library at bentley.ref@umich.edu

April 04, 2013 - Image 19

Resource type:
Text
Publication:
The Detroit Jewish News, 2013-04-04

Disclaimer: Computer generated plain text may have errors. Read more about this.

When it's your heart...why go anywhere else?

Whether you come to Beaumont for an EKG or a heart attack, you'll
find the most advanced heart care - anywhere.

As the leader in minimally invasive heart surgery, Beaumont was
first in the country to use a tiny catheter to replace an aortic valve.
First in Michigan to correct atrial fibrillation robotically. And we
offer minimally invasive treatment for complex aortic aneurysms.

The world's most advanced technology and most experienced
surgeons and cardiologists are right here.

Do you have a Beaumont doctor?

Call 248-551-3728 or visit heart.beaumont.edu

Marc Sakwa, M.D., a second-generation surgeon, is chief of Cardiovascular
Surgery at Beaumont Hospital in Royal Oak. At Beaumont's new Tyner Center
for Cardiovascular Interventions, he and his colleagues are performing ground-
breaking, leading edge procedures for patients with complex heart and vascular
disease. They are also using the center's teaching facility to train other surgeons
on the most innovative procedures and techniques.

1816470

CLINICAL RESEARCH STUDY

ig with

If you have MS,
you may want to
consider this
investigational study_

S ST- ILJ 1:›Y

Learn more about this study for M5:

'Detroit Clinical Research Center, PC
Sonia Amin, BS
(586) 838-1119

If you have relapsing-remitting multiple sclerosis
(I;t1=11 ■ 45) and are between the ages of 16-65, you may

want to join this study evaluating a new investigational

drug that may help reduce your relapses. Participation

is voluntary.

Qualified volunteers will receive study-related
medical evaluations and study drug at no cost.
Compensation for time and reasonable
reimbursement for travel related
expenses are available.

JN

April 4 • 201.

19

Back to Top

© 2025 Regents of the University of Michigan